最新ニュース Cresco Labs (OTC:CRLBF) 株価情報

Cresco Labs

Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products through Sunnyside, Cresco Labs' national dispensary brand and others. The Company operates in one segment, the cultivation, manufacturing, distribution and sale of cannabis.

Cannabis

Earnings

News

Retail Sales

Markets

AAWH

AYRWF

CRLBF

CSE:TRUL

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

TCNNF

TRUL

VRNOF

2024年第2四半期の大部分の大麻企業の財務業績が出揃い、その結果から興味深いトレンドが浮かび上がってきた。その1つが、米国のマルチステート・オペレーター（MSO）が供給チェーンにおけるコストと効率を改善しているという点だ。

大麻関連企業の業績　供給チェーンにおけるコストと効率が改善

Analyst Color

Penny Stocks

Guidance

Emerging Markets

Small Cap

Analyst Ratings

Trading Ideas

CCHWF

令は効率的な運営者の市場占有率の増加と持続可能なプラットフォーム構築を輝かせるだろう。第２四半期の収益を見越して、Zuanic &amp; Associatesのシニアアナリスト、Pablo Zuanic氏は、大麻市場傾向について概要を提供した。

大麻ブームか不況か　正念場の大麻市場

Government

Regulations

Politics

General

CNBS

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

TILT

ペンシルベニア州が最近承認した予算には、大麻企業であるJushi Holdings（OTC：JUSHF）およびTILT Holdings（OTC：TILT）のような企業にとって大きな打撃を与える、大麻の娯楽利用の合法化が除外されています。

ペンシルベニア州　大麻の娯楽利用合法化に制限掲示へ

Cresco Labs Inc

On Wednesday, November 20, U.S. markets closed mixed. The Nasdaq slipped, weighed down by geopolitical tensions and Target&#8217;s disappointing performance. Nvidia declined ahead of earnings, which later underwhelmed. Meanwhile, the Dow edged higher, and the S&amp;P 500 remained flat.
In economic data, U.S. mortgage applications increased by 1.7% for the week ending November 15, up from the 0.5% rise recorded the previous week.
Healthcare, energy, and materials led S&amp;P 500 gains Wednesday, while consumer discretionary and financials declined.
The Dow Jones Industrial Average was up 0.32% and closed at 43,408.47, the S&amp;P 500 gained 0.002% to 5,917.11, and the Nasdaq Composite declined 0.11% to finish at 18,966.14.
Asia Markets Today
<ul>
<li>On Thursday, Japan&#8217;s Nikkei 225 declined 0.97% and ended the session at 38,002.50, led by losses in the Insurance, Transportation Equipment, and Power sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 fell 0.04% and ended the day at 8,323.00, led by losses in the Consumer Discretionary, Consumer Staples, and A-REITs sectors.</li>
<li>India&#8217;s Nifty 50 declined 0.73% to 23,346.70, and Nifty 500 slid 0.85% closing at 21,816.45, led by losses in the Public Sector Undertakings, Oil &amp; Gas and Power sectors.</li>
<li>China&#8217;s Shanghai Composite gained 0.07% to close at 3,370.40, and the Shenzhen CSI 300 rose 0.09%, finishing the day at 3,989.30.</li>
<li>Hong Kong&#8217;s Hang Seng fell 0.53% and closed the session at 19,601.11.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 0.36%.</li>
<li>Germany&#8217;s DAX slid 0.02%.</li>
<li>France&#8217;s CAC declined 0.43%.</li>
<li>FTSE 100 index traded higher by 0.20%</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 1.70% at $69.94/bbl, and Brent was up 1.58% at $73.95/bbl.</li>
<li>Oil prices rose amid escalating Russia-Ukraine missile strikes, overshadowing a larger-than-expected U.S. crude inventory increase.</li>
<li>Natural Gas rose 6.45% to $3.297.</li>
<li>Gold was trading higher by 0.78% at $2,672.45, Silver was up 0.35% to $31.115, and Copper fell 0.83% to $4.1210.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures declined 0.07%, S&amp;P 500 futures were down 0.24% and Nasdaq 100 futures fell 0.35%.
Forex at 05:30 AM ET
The U.S. dollar index gained 0.04% to 106.72, the USD/JPY was down 0.64% to 154.44, and the USD/AUD slid 0.08% to 1.5357.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Mixed; Dollar Hovers Near 52-Week High - Global Markets Today While US Slept

Throughout this NFL-style, three-day combine, prospects from nearly every state are expected to attend, with this year's event expected to host the largest total number of recruits in the event's history and the largest combine-style event in the country.
In connection with their participation in the event, all student-athletes will receive a complimentary one-month trial of the Signing Day Sports app, enhancing their visibility to college recruiters.
By collecting registration fees and offering exclusive apparel for participants and fans, the combine enables the Company to drive immediate income while strengthening its brand presence.&nbsp;
&nbsp;

Signing Day Sports Provides Update On Upcoming 3rd Annual US Army Bowl National Combine; Says Combine Enables Company To Drive Immediate Income While Strengthening Its Brand Presence

China Renaissance analyst Yiwen Zhang downgrades Grab Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) from Buy to Hold and announces $5.4 price target.

Downgrades

Price Target

GRAB

China Renaissance Downgrades Grab Holdings to Hold, Announces $5.4 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) with a Buy and maintains $15 price target.

Reiteration

LSTA

HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

Needham analyst Mike Cikos maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $160 to $200.

SNOW

Needham Maintains Buy on Snowflake, Raises Price Target to $200

<ul>
<li>Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.</li>
<li>BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.</li>
<li>BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.</li>
<li>BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.</li>
<li>Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –</li>
</ul>

Biotech

Health Care

Contracts

BLRX

BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda

Trimble will provide fleet management and telematics solutions to vehicles across PFG's three business segments including Performance Foodservice Core-Mark and Vistar.&nbsp;
All PFG vehicles will be equipped with Trimble Instinct, Trimble's in-cab ecosystem that seamlessly connects drivers and back-office staff to boost safety, compliance and efficiency.
 &nbsp;

PFGC

TRMB

Performance Food Group Selects Trimble As Its Premier Fleet Management Provider; Migrates 100% Of Its Fleet Management Business To Trimble Instinct, Doubling Trimble-Serviced Trucks To Over 8,000

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDD Holdings Q3 Adj EPADS $2.65 Misses $2.82 Estimate, Sales $14.16B Miss $14.47B Estimate

Artificial intelligence (AI) darling Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">beat expectations yet again</a> with impressive third-quarter revenue and earnings reported after Wednesday's market close. 
What happened: The world's most valuable company <a href="https://www.benzinga.com/24/11/42099904/nvidia-q3-earnings-highlights">disclosed </a>third-quarter revenue of $35.1 billion and earnings per share of 81 cents, both beating analysts' estimates.&nbsp;
The Jensen Huang-led firm has had a blockbuster run on equity markets in the last few years, multiplying investors' money by orders of magnitude.&nbsp;
Indeed, Nvidia shares have exploded by 2,718% in the last five years, outperforming all well-known companies on Wall Street.
In comparison, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)—the world's most valued cryptocurrency exerting a similar influence on the digital assets market—grew 1,171% over the last five years.
See Also: <a href="https://www.benzinga.com/24/11/42079799/microstrategys-michael-saylor-to-advocate-for-bitcoin-investment-at-microsoft-board-meeting-offers-to-educate-rumble-ceo-with-the-strategy">Microstrategy&#8217;s Michael Saylor To Advocate For Bitcoin At Microsoft Board Meeting, Offers To Educate Rumble CEO As Well</a>
<h2 class="wp-block-heading">Which Is Offering Better Returns Relative To Risk?</h2>
Both Nvidia and Bitcoin are risk-laden investments, and traders must navigate their inherent volatility to profit.
To get a more accurate picture, analysts track the Sharpe Ratio, a measure of risk-adjusted returns. 
For Bitcoin, this ratio stood at -5 as of this writing, <a href="https://in.tradingview.com/chart/XlzxagWe/?symbol=BITSTAMP%3ABTCUSD">per </a>TradingView, implying that the expected return was lower than that of a risk-free investment, such as a Treasury yield.&nbsp;
On the other hand, Nvidia <a href="https://www.tradingview.com/chart/XlzxagWe/?symbol=NASDAQ%3ANVDA">showed </a>a Sharpe ratio of 0.69, indicating that investment in the stock was generating positive returns above the risk-free rate.
<h2 class="wp-block-heading">Are Their Valuations Inflated?</h2>
Another metric to compare the two hot financial assets was whether they were expensive or cheap relative to their fundamentals.
For stocks, this is typically measured by the price-to-earnings ratio, or simply the P/E ratio.&nbsp;
Nvidia's P/E ratio showed a reading of 73.478 per TradingView, suggesting that the stock was highly overpriced. It could also imply that investors expect the company to have stronger performance and higher earnings in the future.
The P/E counterpart for Bitcoin is the network value to transactions ratio or NVT ratio.
According to on-chain analytics firm <a href="https://cryptoquant.com/asset/btc/chart/network-indicator/nvt-ratio?window=DAY&amp;sma=0&amp;ema=0_30&amp;priceScale=log&amp;metricScale=log&amp;chartStyle=column">CryptoQuant</a>, the 30-day EMA of Bitcoin's NVT was at 28.28 at the time of writing, a decline from 36.32 recorded at the beginning of the month.
The decline implied that transaction volume was outperforming market growth or that valuation had dropped without any change in transaction activity.
Price Action: At the time of writing, Bitcoin was trading at $97,396.60, rising 4.97% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of Nvidia were down 2.49% in after-hours trading.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42079984/dogecoin-bitcoin-left-in-the-dust-by-ai-meme-coin-goat-as-nvidias-q3-earnings-draw-near">Dogecoin, Bitcoin Left In The Dust By AI Meme Coin GOAT As Nvidia&#8217;s Q3 Earnings Draw Near</a></li>
</ul>
Photos courtesy: Nvidia and Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Tech

$BTC

NVDA

Nvidia Vs. Bitcoin: Jensen Huang-Led Chip Giant's Stock Outperformed The Top Cryptocurrency Over 5 Years. Here's How They Compare On Other Metrics

Benchmark analyst Cody Acree maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $170 to $190.

Benchmark Maintains Buy on NVIDIA, Raises Price Target to $190

Roth MKM analyst Joe Reagor initiates coverage on Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) with a Buy rating and announces Price Target of $13.

Initiation

SDST

Roth MKM Initiates Coverage On Stardust Power with Buy Rating, Announces Price Target of $13

Morgan Stanley analyst James Faucette upgrades Evertec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from Underweight to Equal-Weight and raises the price target from $33 to $35.

Upgrades

EVTC

Morgan Stanley Upgrades Evertec to Equal-Weight, Raises Price Target to $35

Morgan Stanley analyst Brian Wilczynski initiates coverage on UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Overweight rating and announces Price Target of $156.

UMBF

Morgan Stanley Initiates Coverage On UMB Financial with Overweight Rating, Announces Price Target of $156

Needham analyst Quinn Bolton maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $145 to $160.

Needham Maintains Buy on NVIDIA, Raises Price Target to $160

Morgan Stanley analyst Judah Frommer initiates coverage on 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Underweight rating and announces Price Target of $8.

FDMT

Morgan Stanley Initiates Coverage On 4D Molecular Therapeutics with Underweight Rating, Announces Price Target of $8

Morgan Stanley analyst Judah Frommer initiates coverage on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight rating and announces Price Target of $31.

APLS

Morgan Stanley Initiates Coverage On Apellis Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $31

Quantum-Si Provides Update On Innovation Roadmap & New Development Partnerships; Announces Next-Generation Platinum System, The Platinum Pro, Scheduled To Launch In H1 Of 2025

SCVL

Shoe Carnival Lowers FY24 Net Sales Outlook: Sees Revenues Of $1.20B-$1.23B Vs $1.23B Estimate (Prior View:  $1.23B-$1.25B); Company Reiterates FY24 Adjusted EPS Outlook Of $2.60-$2.75 Vs. $2.63 Estimate

With more than a week of deals planned across the entire assortment, Target will offer some of its lowest prices of the season on thousands of items, including up to 50% off tech, apparel, video games, board games, small appliances, luggage, holiday trees and other must-have items for gifting and gathering.

Target Reveals Its Lineup Of Black Friday Deals Available Now Through Nov. 30 Online And In Its Stores

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) with a Buy and raises the price target from $4 to $5.5.

HC Wainwright & Co. Maintains Buy on Quantum-Si, Raises Price Target to $5.5

Here's the major earnings before the open tomorrow

Cresco Labs reports Q3 results

Cresco Labs Inc. (CRLBF) Q3 2024 Earnings Call Transcript

While the Florida initiative for cannabis legalization didn't reach the 60% needed to pass (only 56%).

Cresco Labs Q3: Net Loss Reduced By 85% But EBITDA Also Declined By 5%

Cresco Labs OTC ( ($CRLBF) ) has released its Q3 earnings. Here is a breakdown of the information Cresco Labs OTC presented to its investors. Cresc...

Cresco Labs Reports Robust Q3 2024 Financial Performance

Cormark downgraded Cresco Labs (CRLBF) to Market Perform from Speculative Buy with a C$2.75 price target Published first on TheFly – the ultimate s...

Cresco Labs downgraded to Market Perform from Speculative Buy at Cormark

Haywood analyst Neal Gilmer reiterated a Buy rating on Cresco Labs (CRLBF – Research Report) today and set a price target of C$2.80. The company's ...

Haywood Reaffirms Their Buy Rating on Cresco Labs (CRLBF)

Weed stocks spike after report on Trump support for marijuana reforms

Cannabis stocks gain as Trump picks pro-marijuana Congressman Gaetz for AG post

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, a Phase 3 ...

Rising High: Cannabis firms report quarterly earnings

ACRHF

ADNT

AMCX

AMRX

ANIP

ATAI

ATSG

BEPC

BLMN

CANN

CBWTF

CMPS

CRON

CVSI

CYBN

DCBO

ENVB

FLGT

GRWG

HUMA

ICAGY

IFRX

ILLMF

IMCC

LAMR

MEDIF

MSOS

NLCP

OCGN

PAGP

PARAA

PLNH

QTRHF

RCMT

RLMD

SHFS

SONY

TLRY

TSNDF

VREOF

XERS

YOLO

Press Releases

Cresco Labs Reports Continued Trend of Financial Improvement with First Quarter 2024 Financial Results

Cresco Labs Announces Voting Results of Its Annual General and Special Meeting of Shareholders

Cresco Labs to Report Second Quarter 2024 Financial Results on August 8, 2024

Cresco Labs Launches Adult-Use Cannabis Distribution and Retail Sales in Ohio

Cresco Labs Reports Consistent Profitability Improvement with Second Quarter 2024 Financial Results

National Leading Vape Brand, Bloom, Partners With Cresco Labs to Launch Products in Florida

Cresco Labs Announces Dennis Olis to Retire as Chief Financial Officer

Cresco Labs Announces Resignation from the Board

Cresco Labs to Report Third Quarter 2024 Financial Results on November 8, 2024

Cresco Labs Demonstrates Success of Cash Flow Focused Strategy with Third Quarter 2024 Financial Results

Comments

Cresco Labs

ニュース

最新ニュース Cresco Labs (OTC:CRLBF) 株価情報

月曜日, 8 12, 2024

水曜日, 8 07, 2024

火曜日, 7 16, 2024

水曜日, 6 26, 2024

水曜日, 6 19, 2024

火曜日, 5 07, 2024

木曜日, 4 18, 2024

ニュース

パートナーシップ

ベンジンガ・グローバル